To evaluate whether StrataGraft treatment promotes wound closure and reduces or
eliminates the need for donor site harvest and autografting in a pediatric population with thermal burns that contain intact dermal elements and for which autografting would be part of standard of care (deep partial-thickness [DPT] burns). Study assessments will include the incidence of adverse events (AEs), including wound
infection, and additionally monitoring of vital signs, clinical laboratory values, immunological values (where possible), wound closure, including any autografting, and skin quality of the treatment site.

The objective of this study is to evaluate the efficacy of augmenting traditional autografting with Stratagraft. Stratagraft is a synthetic human-tissue based regenerative skin device, which was designed to decrease the amount of donor tissue needed to treat severe burn wounds. Patients who participate in this study are asked to complete assessments, such as wound photography, wound healing progression, and scar progression, at multiple timepoints during a 1 year period.